TORONTO, 20 June 2016 – Profound Medical Corp. (TSXV:PRN) ("Profound" or "the Company"), an emerging medical device company focused on prostate care, today announced that it and Royal Philips (“Philips”) have jointly sold a TULSA-PROTM system in the United Kingdom to UCL (University College London) and University College London Hospitals NHS Foundation Trust (UCLH).

This marks the first sale under the Company’s recent collaboration with Philips, following Profound’s receipt of CE Mark approval in April 2016.

Professor Mark Emberton, Dean, UCL Faculty of Medical Sciences and Professor of Interventional Oncology, is well-known for his thought leadership on novel imaging techniques and minimally-invasive treatments in Europe.
Prof. Emberton, who also holds a post as an honorary consultant urologist at UCLH, commented, “We are delighted to be able to offer the TULSA procedure to our patients at UCLH in the very near future. This innovative technology is a compelling therapeutic option for prostate ablation in patients with localized prostate cancer. I am intrigued at investigating its promising versatility, in the course of time, as a focal therapy option.”

Steve Plymale, Profound Medical CEO, added, “We are pleased to complete the second sale of our TULSA-PRO system. We anticipate that UCLH will become an active centre for TULSA procedures in the United Kingdom. Our partnership with such luminary institutions such as UCL and UCLH will help us broaden awareness, acceptance and adoption of TULSA-PRO amongst clinicians and patients in Europe.”

TULSA-PRO is a unique technology that combines real-time Magnetic Resonance Imaging (MRI) with transurethral robotically-driven ultrasound and closed-loop thermal feedback control providing a highly precise prostate treatment tailored to patient-specific anatomy. It has demonstrated accurate and precise ablation of malignant prostate tissue, while providing a favourable safety profile, with low rates of serious or long-term adverse events.

About Profound Medical Corp.
Profound is a Canadian medical device company that developed a unique and minimally invasive procedure to ablate malignant prostate tissue. The Company’s novel technology combines real-time Magnetic Resonance imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control. It provides a highly precise treatment tailored to patient-specific anatomy and pathology. This method of prostate ablation offers short treatment times and low morbidity, allowing for fast patient recovery. For more information, visit www.profoundmedical.com

Back to HCB News

European Press Room Homepage